Combination therapy using parthenolide and doxorubicin induces apoptosis in Raji cells: insights into miR-27b and signaling pathway alterations.

Zahra Zare-Badie, Farahnaz Zare, Banafsheh Rastegari, Gholamhossein Tamaddon

Abstract read

In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zahra Zare-BadieDivision of Hematology and Blood Banking, Department of Laboratory Science, School of Paramedical Science, Shiraz University of Medical Science, Shiraz, Iran.

Farahnaz ZareDiagnostic Laboratory Science and Technology Research Center, School of Paramedical Science, Shiraz University of Medical Science, Shiraz, Iran.

Banafsheh RastegariDiagnostic Laboratory Science and Technology Research Center, School of Paramedical Science, Shiraz University of Medical Science, Shiraz, Iran.

Gholamhossein TamaddonDivision of Hematology and Blood Banking, Department of Laboratory Science, School of Paramedical Science, Shiraz University of Medical Science, Shiraz, Iran. tamaddon.g@gmail.com.

Funding

Shiraz University of Medical Sciences 28162

6 · The paper itself

Abstract

Burkitt lymphoma, a highly aggressive form of non-Hodgkin lymphoma, have significant treatment challenges, such as chemotherapy-related toxicity and the risk of relapse, especially in older adults. Treatment of Raji cells, a Burkitt lymphoma cell line, with parthenolide in combination to doxorubicin may enhance therapeutic efficacy. This study aimed to evaluate cell viability and apoptosis following treatment with these agents, and to investigate the underlying molecular mechanisms involving miR-27b and the MET/PI3K/AKT signaling pathway. Raji cells were treated with varying concentrations of parthenolide and doxorubicin for 48 and 72 h, cell viability was assessed using the MTT assay, and apoptosis was quantified using flow cytometry. Subsequently, we performed quantitative RT-PCR to evaluate the expression levels of miR-27b, MET, PI3K, and AKT. The half-maximum inhibitory concentration (IC

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsApoptosisBurkitt LymphomaDoxorubicinMicroRNAsSesquiterpenesCell Line, TumorCell SurvivalHumansPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-metSignal TransductionDoxorubicinMicroRNAsMIRN27 microRNA, humanparthenolidePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-metSesquiterpenesApoptosisBurkitt lymphomaDoxorubicinmiR-27bParthenolideRaji cells

Identifiers

PMID40072647

DOI10.1007/s12032-025-02673-w

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.